Learn more: PMC Disclaimer | PMC Copyright Notice
Re: ‘Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients’ by Fiolet et al.
To the Editor,
We read with interest the paper by Fiolet et al. entitled “Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: a systematic review and meta-analysis” recently published in Clinical Microbiology and Infection 2020 [1].
Further to this article we performed an extensive literature review and found many other studies dealing with the same topic that were published in good-quality peer-reviewed journals. But regrettably these were not considered by the authors despite their having performed (as they stated) an extensive research of the literature, as mentioned in their ‘Material and methods’ section [1].
The essence of a systematic review is that it should take into account all the data in order to make a rigorous, open and fair-minded synthesis on the topic. At least three meaningful studies that met the inclusion/exclusion criteria and were in favour of the efficacy of hydroxychloroquine and azithromycin in COVID-19 patients were discarded [[2], [3], [4]]. This approach is more akin to cherry-picking than to a true systematic review without a priori considerations.
Furthermore, the authors acknowledge in their article that only one study included non-hospitalized outpatients. Fiolet et al. stated: “Despite our inclusion criteria that did not specify the stage of the disease, all the studies were conducted with hospitalized patients except the RCT by Skipper et al.” [1]. In Skipper's study, although the difference was not statistically significant due to the small number of patients included [5], there were twice as many hospitalized patients in the placebo group (four hospitalizations out of 231 patients with hydroxychloroquine versus ten hospitalizations out of 234 patients with placebo). Last but not least, only 34% of those patients received appropriate PCR testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which adds to the confusion.
Heart rhythm disorders might be prevented in the hospital environment by monitoring with ECG and serum potassium measurement. The ‘recovery’ study did not meet the inclusion criteria as non-PCR-tested patients were included [6]. In addition, the doses of hydroxychloroquine given to COVID-19 patients in this study (2400 mg on the first day, followed by 9 days at 800 mg/day) were high and thus potentially toxic.
We are awaiting appropriate clinical trials or a thorough systematic review and meta-analysis to close the French and worldwide debate on whether treating patients with hydroxychloroquine/azithromycin in the early phase of COVID-19 infection improves their outcome.
Author contributions
AL: conceptualization, writing original draft. PYM: writing, review and editing. CP: supervision.
Transparency declaration
The authors have no conflicts of interest to disclose. No external funding was received.
Notes
Editor: L. Leibovici